Investment Rating - The investment rating for the company is "Buy" and is maintained [6] Core Insights - The company reported a revenue of 3.291 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 7.96%. The net profit attributable to the parent company was 260 million yuan, up 8.53% year-on-year, while the net profit excluding non-recurring items was 244 million yuan, an increase of 3.42% year-on-year. In Q3 2025 alone, the company achieved a revenue of 1.250 billion yuan, a year-on-year increase of 18.11%, with a net profit of 99.15 million yuan, up 16.20% year-on-year, and a net profit excluding non-recurring items of 84.96 million yuan, an increase of 3.75% year-on-year [2][4][11] Financial Performance - The gross profit margin for the first three quarters of 2025 increased by 1.05 percentage points to 32.26%, while the net profit margin attributable to the parent company rose by 0.04 percentage points to 7.91%. In Q3 2025, the gross profit margin was 30.76%, up 1.12 percentage points year-on-year [11] - The company is expected to achieve net profits of 341 million yuan, 431 million yuan, and 538 million yuan for 2025, 2026, and 2027 respectively, corresponding to PE ratios of 22, 18, and 14 times [11] Business Outlook - The company is experiencing steady business recovery and product structure optimization, with a positive long-term growth outlook. The internal business profitability is strong, although some production lines are exerting pressure on profits. The company is in the process of selling certain production lines, which may enhance its growth potential [11]
仙乐健康(300791):业务修复稳步推进,产品结构优化